$CERS
Cerus Corp Stock $cers

$cers Overview Financials Valuation SEC Filings Company Website

2011 Q4 Form 10-K Financial Statement

#000119312513103031 Filed on March 12, 2013

Income Statement

Concept	2011 Q4	2011 Q3	2011 Q2
Revenue	$9.896M	$7.770M	$6.753M
YoY Change	53.19%	55.71%	13.69%
Cost Of Revenue	$6.206M	$4.726M	$4.074M
YoY Change	70.96%	103.71%	39.04%
Gross Profit	$3.690M	$3.044M	$2.679M
YoY Change	30.39%	14.01%	-10.7%
Gross Profit Margin	37.29%	39.18%	39.67%
Selling, General & Admin	$5.938M	$5.380M	$6.207M
YoY Change	0.47%	5.7%	17.11%
% of Gross Profit	160.92%	176.74%	231.69%
Research & Development	$1.562M	$1.814M	$1.994M
YoY Change	10.0%	41.72%	60.81%
% of Gross Profit	42.33%	59.59%	74.43%
Depreciation & Amortization	$220.0K	$180.0K	$250.0K
YoY Change	-24.14%	-5.26%	38.89%
% of Gross Profit	5.96%	5.91%	9.33%
Operating Expenses	$7.550M	$7.245M	$8.252M
YoY Change	2.03%	13.74%	25.98%
Operating Profit	-$3.333M	-$2.722M	-$5.573M
YoY Change	-27.07%	-26.43%	56.99%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$4.353M	$5.026M	-$809.0K
YoY Change	-780.16%	-50360.0%	2596.67%
Pretax Income	-$7.686M	$2.304M	-$6.382M
YoY Change	227.06%	-163.47%	14.78%
Income Tax	$49.00K	$44.00K	$27.00K
% Of Pretax Income		1.91%
Net Earnings	-$7.735M	$2.260M	-$6.409M
YoY Change	215.71%	-162.26%	15.27%
Net Earnings / Revenue	-78.16%	29.09%	-94.91%
Basic Earnings Per Share	-$0.16	$0.05	-$0.13
Diluted Earnings Per Share	-$0.16	$0.05	-$0.13
COMMON SHARES
Basic Shares Outstanding		47.71M
Diluted Shares Outstanding

Balance Sheet

Concept	2011 Q4	2011 Q3	2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$25.80M	$15.20M	$17.80M
YoY Change	-14.0%	15.15%	11.95%
Cash & Equivalents	$25.50M
Short-Term Investments	$300.0K	$7.200M	$7.200M
Other Short-Term Assets	$605.0K	$1.100M	$900.0K
YoY Change	-39.5%	-8.33%	-30.77%
Inventory	$6.444M	$9.600M	$10.00M
Prepaid Expenses	$810.0K
Receivables	$6.096M	$4.800M	$4.400M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$39.74M	$30.70M	$33.00M
YoY Change	-4.93%	21.34%	22.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.032M	$2.000M	$2.100M
YoY Change	-15.33%	-23.08%	23.53%
Goodwill	$1.316M
YoY Change
Intangibles	$1.748M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$229.0K	$700.0K	$800.0K
YoY Change	-71.38%	-12.5%	-38.46%
Total Long-Term Assets	$5.628M	$5.900M	$6.100M
YoY Change	-12.06%	-14.49%	103.33%
TOTAL ASSETS
Total Short-Term Assets	$39.74M	$30.70M	$33.00M
Total Long-Term Assets	$5.628M	$5.900M	$6.100M
Total Assets	$45.37M	$36.60M	$39.10M
YoY Change	-5.88%	13.66%	30.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.680M	$3.800M	$4.700M
YoY Change	46.25%	22.58%	34.29%
Accrued Expenses	$5.825M	$5.700M	$5.300M
YoY Change	-2.92%	11.76%	29.27%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.500M	$0.00	$1.900M
YoY Change	38.89%	-100.0%	137.5%
Total Short-Term Liabilities	$21.11M	$14.20M	$22.10M
YoY Change	7.18%	-3.4%	70.0%
LONG-TERM LIABILITIES
Long-Term Debt	$4.700M	$4.900M	$2.200M
YoY Change	51.61%	36.11%	-45.0%
Other Long-Term Liabilities	$1.243M	$1.300M	$1.600M
YoY Change	-22.31%	-13.33%	128.57%
Total Long-Term Liabilities	$1.243M	$6.200M	$3.800M
YoY Change	-73.55%	21.57%	-19.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.11M	$14.20M	$22.10M
Total Long-Term Liabilities	$1.243M	$6.200M	$3.800M
Total Liabilities	$27.05M	$20.40M	$25.90M
YoY Change	10.88%	2.51%	45.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$443.9M
YoY Change
Common Stock	$51.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.31M	$16.20M	$13.20M
YoY Change
Total Liabilities & Shareholders Equity	$45.37M	$36.60M	$39.10M
YoY Change	-5.88%	13.66%	30.77%

Cashflow Statement

Concept	2011 Q4	2011 Q3	2011 Q2
OPERATING ACTIVITIES
Net Income	-$7.735M	$2.260M	-$6.409M
YoY Change	215.71%	-162.26%	15.27%
Depreciation, Depletion And Amortization	$220.0K	$180.0K	$250.0K
YoY Change	-24.14%	-5.26%	38.89%
Cash From Operating Activities	-$1.080M	-$3.510M	-$5.980M
YoY Change	-73.4%	80.93%	151.26%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	-$50.00K	-$20.00K
YoY Change		-94.38%	-97.3%
Acquisitions
YoY Change
Other Investing Activities	$310.0K	$160.0K	$40.00K
YoY Change	10.71%	-60.98%	-90.0%
Cash From Investing Activities	$270.0K	$110.0K	$20.00K
YoY Change	-3.57%	-122.92%	-106.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.55M	1.000M	-480.0K
YoY Change	-44.6%	525.0%	-1700.0%
NET CHANGE
Cash From Operating Activities	-1.080M	-3.510M	-5.980M
Cash From Investing Activities	270.0K	110.0K	20.00K
Cash From Financing Activities	11.55M	1.000M	-480.0K
Net Change In Cash	10.74M	-2.400M	-6.440M
YoY Change	-37.08%	6.19%	140.3%
FREE CASH FLOW
Cash From Operating Activities	-$1.080M	-$3.510M	-$5.980M
Capital Expenditures	-$40.00K	-$50.00K	-$20.00K
Free Cash Flow	-$1.040M	-$3.460M	-$5.960M
YoY Change	-74.38%	229.52%	263.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2010Q3	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Amount BusinessAcquisitionPurchasePriceAllocationGoodwillAmount	1316000
CY2010Q3	us-gaap	Business Acquisition Purchase Price Allocation Intangible Assets Other Than Goodwill BusinessAcquisitionPurchasePriceAllocationIntangibleAssetsOtherThanGoodwill	2017000
CY2010Q3	us-gaap	Business Acquisition Purchase Price Allocation Other Assets BusinessAcquisitionPurchasePriceAllocationOtherAssets	135000
CY2010Q3	us-gaap	Business Acquisition Purchase Price Allocation Assets Acquired BusinessAcquisitionPurchasePriceAllocationAssetsAcquired	3738000
CY2010Q3	us-gaap	Business Acquisition Purchase Price Allocation Current Assets Inventory BusinessAcquisitionPurchasePriceAllocationCurrentAssetsInventory	270000
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60103000	shares
CY2012Q2	dei	Entity Public Float EntityPublicFloat	135400000
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	21448000
CY2009Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.38
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17287000
CY2011Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	84000
CY2011Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1062000
CY2011Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.70
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4065000
CY2009Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6565000	shares
CY2010Q4	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Fair Value BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue	0
CY2010Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Equity Interests Issued And Issuable BusinessAcquisitionCostOfAcquiredEntityEquityInterestsIssuedAndIssuable	3400000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4323000	shares
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	23732000
CY2010Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	922000
CY2010Q4	us-gaap	Business Acquisition Purchase Price Allocation Tangible Assets BusinessAcquisitionPurchasePriceAllocationTangibleAssets	2400000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.93
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2761000
CY2010Q4	us-gaap	Business Acquisition Purchase Price Allocation Noncontrolling Interest BusinessAcquisitionPurchasePriceAllocationNoncontrollingInterest	300000
CY2010Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	8465000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.42
CY2010Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Purchase Price BusinessAcquisitionCostOfAcquiredEntityPurchasePrice	3700000
CY2010Q4	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Percentage BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage	0.13	pure
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2610000
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28948000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6705000	shares
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7007000	shares
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.60
CY2011Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	4697000
CY2011Q4	us-gaap	Goodwill Goodwill	1316000
CY2011Q4	us-gaap	Entity Wide Disclosure On Geographic Areas Long Lived Assets In Foreign Countries EntityWideDisclosureOnGeographicAreasLongLivedAssetsInForeignCountries	650000
CY2011Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	3900000
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10067000
CY2011Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2011Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	7300000
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	605000
CY2011Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2742000
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	191300000
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	229000
CY2011Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	24000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4058000	shares
CY2011Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	31400000
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	18313000
CY2011Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1748000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	200000
CY2011Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	8970000
CY2011Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1682000
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2011Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	38000
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2381000
CY2011Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1902000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	400000
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	112500000	shares
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2027000
CY2011Q4	us-gaap	Secured Debt SecuredDebt	7216000
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	4200000
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5825000
CY2011Q4	us-gaap	Entity Wide Disclosure On Geographic Areas Long Lived Assets In Entitys Country Of Domicile EntityWideDisclosureOnGeographicAreasLongLivedAssetsInEntitysCountryOfDomicile	3299000
CY2011Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	2519000
CY2011Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	636000
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21114000
CY2011Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	7979000
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	5000
CY2011Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3702000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	200000
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45367000
CY2011Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5598000
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	303000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	3835000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25497000
CY2011Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2017000
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51211000	shares
CY2011Q4	us-gaap	Fair Value Liabilities Measured On Recurring Basis Obligations FairValueLiabilitiesMeasuredOnRecurringBasisObligations	7979000
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1748000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6900000	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51211000	shares
CY2011Q4	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	6444000
CY2011Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	9496000
CY2011Q4	us-gaap	Liabilities Liabilities	27054000
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4680000
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2011Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	287000
CY2011Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	810000
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	137800000
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	111000
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1243000
CY2011Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	7979000
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-443935000
CY2011Q4	us-gaap	Assets Assets	45367000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.70
CY2011Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	600000
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6096000
CY2011Q4	us-gaap	Inventory Net InventoryNet	6444000
CY2011Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	0
CY2011Q4	us-gaap	Assets Current AssetsCurrent	39739000
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3000	shares
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7362000	shares
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	51000
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	269000
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	191300000
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	3000	shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue	9496000
CY2011Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	500000
CY2011Q4	cers	Debt Instrument Carrying Non Current DebtInstrumentCarryingNonCurrent	4746000
CY2011Q4	cers	Debt Instrument Carrying Current DebtInstrumentCarryingCurrent	2554000
CY2011Q4	cers	Inventory Write Down Against Which Offsetting Warranty Claim Available InventoryWriteDownAgainstWhichOffsettingWarrantyClaimAvailable	0
CY2012Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	2896000
CY2012Q4	us-gaap	Goodwill Goodwill	1316000
CY2012Q4	us-gaap	Entity Wide Disclosure On Geographic Areas Long Lived Assets In Foreign Countries EntityWideDisclosureOnGeographicAreasLongLivedAssetsInForeignCountries	349000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	865000
CY2012Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	3900000
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10020000
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2012Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	7773000
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2038000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	19107000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1546000
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8035000
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2032000
CY2011Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	0
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	452701000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.86
CY2011Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	8970000
CY2011Q4	cers	Computer Equipment Gross ComputerEquipmentGross	525000
CY2011Q4	cers	Entity Wide Disclosure On Geographic Areas Long Lived Assets Total EntityWideDisclosureOnGeographicAreasLongLivedAssetsTotal	3949000
CY2011Q4	cers	Deferred Tax Assets Acquisition Related Costs DeferredTaxAssetsAcquisitionRelatedCosts	200000
CY2011Q4	cers	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	1400000
CY2011Q4	cers	Deferred Tax Liabilities Amortization Of Intangible Assets DeferredTaxLiabilitiesAmortizationOfIntangibleAssets	0
CY2011Q4	cers	Accrued Inventory AccruedInventory	1417000
CY2011Q4	cers	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	10300000
CY2011Q4	cers	Cumulative Outstanding Trade Receivables Number Of Major Customers CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers	2	Customer
CY2011Q4	cers	Cumulative Outstanding Trade Receivables Major Customers Percentage CumulativeOutstandingTradeReceivablesMajorCustomersPercentage	0.58	pure
CY2011Q4	cers	Debt Instrument Unamortized Noncurrent DebtInstrumentUnamortizedNoncurrent	49000
CY2011Q4	cers	Debt Instrument Unamortized Current DebtInstrumentUnamortizedCurrent	35000
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3551000
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	190500000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	59000
CY2012Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1334000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	200000
CY2012Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	24000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5150000	shares
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	30800000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	45000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	200000
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	10268000
CY2012Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1594000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	55000
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2575000
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3582000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	100000
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	112500000	shares
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	200000
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2692000
CY2012Q4	us-gaap	Secured Debt SecuredDebt	7724000
CY2012Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	49000
CY2012Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1062000
CY2012Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	62000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.77
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5433000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56252000	shares
CY2012Q4	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	10180000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	350000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	838000
CY2012Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0
CY2012Q4	us-gaap	Liabilities Liabilities	29812000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7186000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	0
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	638000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	137700000
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	77000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1241000
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	5903000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	4000
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Sales Revenue Goods Net Percentage SalesRevenueGoodsNetPercentage	0.10	pure
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-459852000
CY2012Q4	us-gaap	Assets Assets	48919000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.40
CY2012Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	62000
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4444000
CY2012Q4	us-gaap	Inventory Net InventoryNet	10180000
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	0
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	4800000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48919000
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5598000
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	304000
CY2012Q4	us-gaap	Cost Method Investments Aggregate Carrying Amount CostMethodInvestmentsAggregateCarryingAmount	0
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	5310000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26696000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2017000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56252000	shares
CY2012Q4	us-gaap	Fair Value Liabilities Measured On Recurring Basis Obligations FairValueLiabilitiesMeasuredOnRecurringBasisObligations	5903000
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1546000
CY2012Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	5084000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8140000	shares
CY2012Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12900000	shares
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7619000
CY2012Q4	us-gaap	Entity Wide Disclosure On Geographic Areas Long Lived Assets In Entitys Country Of Domicile EntityWideDisclosureOnGeographicAreasLongLivedAssetsInEntitysCountryOfDomicile	2895000
CY2012Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	4828000
CY2012Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	644000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	200000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	200000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25613000
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	5903000
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6629000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	700000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8504000	shares
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	56000
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	471000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	43996000
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	190500000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	200000
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2012Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	900000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2102000
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8322000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1698000
CY2012Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	100000
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	478903000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.42
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	10268000
CY2012Q4	cers	Computer Equipment Gross ComputerEquipmentGross	550000
CY2012Q4	cers	Entity Wide Disclosure On Geographic Areas Long Lived Assets Total EntityWideDisclosureOnGeographicAreasLongLivedAssetsTotal	3244000
CY2012Q4	cers	Deferred Tax Assets Acquisition Related Costs DeferredTaxAssetsAcquisitionRelatedCosts	200000
CY2012Q4	cers	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	1300000
CY2012Q4	cers	Longterm Debt Maturities Repayments Of Principal In Year One LongtermDebtMaturitiesRepaymentsOfPrincipalInYearOne	2063000
CY2012Q4	cers	Deferred Tax Liabilities Amortization Of Intangible Assets DeferredTaxLiabilitiesAmortizationOfIntangibleAssets	62000
CY2012Q4	cers	Long Term Purchase Commitment Amount Due Within One Year LongTermPurchaseCommitmentAmountDueWithinOneYear	2500000
CY2012Q4	cers	Long Term Purchase Commitment Amount Due Within Three Years LongTermPurchaseCommitmentAmountDueWithinThreeYears	100000
CY2010	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M29D
CY2010	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	607000
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1828000
CY2010	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16861000
CY2010	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1545000
CY2010	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	94000
CY2010	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	19.20
CY2010	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5718000
CY2010	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y29D
CY2010	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	853000
CY2010	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	1828000
CY2010	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.90
CY2012Q4	cers	Long Term Purchase Commitment Amount Due Within Two Years LongTermPurchaseCommitmentAmountDueWithinTwoYears	100000
CY2012Q4	cers	Finite Lived Intangible Assets Amortization Expense Year Six FiniteLivedIntangibleAssetsAmortizationExpenseYearSix	200000
CY2012Q4	cers	Accrued Inventory AccruedInventory	2352000
CY2012Q4	cers	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	9100000
CY2012Q4	cers	Cumulative Outstanding Trade Receivables Number Of Major Customers CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers	3	Customer
CY2012Q4	cers	Cumulative Outstanding Trade Receivables Major Customers Percentage CumulativeOutstandingTradeReceivablesMajorCustomersPercentage	0.59	pure
CY2012Q4	cers	Debt Instrument Unamortized Noncurrent DebtInstrumentUnamortizedNoncurrent	20000
CY2012Q4	cers	Debt Instrument Unamortized Current DebtInstrumentUnamortizedCurrent	29000
CY2012Q4	cers	Finite Lived Intangible Assets Amortization Expense Year Nine FiniteLivedIntangibleAssetsAmortizationExpenseYearNine	100000
CY2012Q4	cers	Debt Instrument Carrying Non Current DebtInstrumentCarryingNonCurrent	2916000
CY2012Q4	cers	Debt Instrument Carrying Current DebtInstrumentCarryingCurrent	4857000
CY2012Q4	cers	Finite Lived Intangible Assets Amortization Expense Year Seven FiniteLivedIntangibleAssetsAmortizationExpenseYearSeven	200000
CY2012Q4	cers	Leasehold Improvement Reflected In Accrued Liabilities LeaseholdImprovementReflectedInAccruedLiabilities	100000
CY2012Q4	cers	Options And Other Stock Based Awards OptionsAndOtherStockBasedAwards	8600000	shares
CY2012Q4	cers	Finite Lived Intangible Assets Amortization Expense Year Eight FiniteLivedIntangibleAssetsAmortizationExpenseYearEight	200000
CY2012Q4	cers	Inventory Write Down Against Which Offsetting Warranty Claim Available InventoryWriteDownAgainstWhichOffsettingWarrantyClaimAvailable	1700000
CY2012Q4	cers	Leasehold Improvement Reflected In Other Non Current Liabilities LeaseholdImprovementReflectedInOtherNonCurrentLiabilities	700000
CY2012Q4	cers	Outstanding Liability Related To Leasehold Improvements Current And Non Current OutstandingLiabilityRelatedToLeaseholdImprovementsCurrentAndNonCurrent	800000
CY2012Q4	cers	Product Warranty Receivable Current ProductWarrantyReceivableCurrent	1800000
CY2011Q1	us-gaap	Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued	234471	shares
CY2010Q3	us-gaap	Business Acquisition Effective Date Of Acquisition1 BusinessAcquisitionEffectiveDateOfAcquisition1	2010-08-24
CY2010Q3	us-gaap	Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued	937886	shares
CY2010	us-gaap	Costmethod Investments Realized Gain Loss Excluding Other Than Temporary Impairments CostmethodInvestmentsRealizedGainLossExcludingOtherThanTemporaryImpairments	315000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	-15958000
CY2010	us-gaap	Revenue From Grants RevenueFromGrants	1432000
CY2010	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	21677000
CY2010	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1193000
CY2010	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	19291000
CY2010	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2010	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.03
CY2010	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2010	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5195000
CY2010	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	7200000
CY2010	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	202000	shares
CY2010	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	0
CY2010	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-1561000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	309000	shares
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	439000
CY2010	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-113000
CY2010	us-gaap	Other Noncash Expense OtherNoncashExpense	152000
CY2010	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2010	us-gaap	Depreciation And Amortization DepreciationAndAmortization	600000
CY2010	us-gaap	Entity Wide Disclosure On Geographic Areas Revenue From External Customers Attributed To Foreign Countries EntityWideDisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToForeignCountries	21677000
CY2010	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	500000
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14268000
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70000
CY2010	us-gaap	Income Taxes Paid IncomeTaxesPaid	114000
CY2010	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2010	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-97000
CY2010	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.62
CY2010	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0
CY2010	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16948000
CY2010	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1692000
CY2010	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11661000
CY2010	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-99000
CY2010	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	34000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	981000	shares
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40300000	shares
CY2010	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2010	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1167000
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16817000
CY2010	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	95000
CY2010	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	50000
CY2010	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25999000
CY2010	us-gaap	Dilutive Securities DilutiveSecurities	0
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	28000	shares
CY2010	us-gaap	Operating Leases Rent Expense Minimum Rentals OperatingLeasesRentExpenseMinimumRentals	900000
CY2010	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	300000
CY2010	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2010	us-gaap	Operating Expenses OperatingExpenses	27021000
CY2010	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6544000
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-17256000
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40300000	shares
CY2010	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2066000
CY2010	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2010	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2010	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	4811000
CY2010	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1710000
CY2010	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M19D
CY2010	us-gaap	Cost Of Goods Sold CostOfGoodsSold	12046000
CY2010	us-gaap	Revenues Revenues	23109000
CY2010	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	94000
CY2010	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	11000
CY2010	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1828000
CY2010	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0
CY2010	us-gaap	Gross Profit GrossProfit	9631000
CY2010	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	88000
CY2010	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0
CY2010	us-gaap	Interest Paid InterestPaid	600000
CY2010	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2010	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9867000	shares
CY2010	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2010	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	370000
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-16911000
CY2010	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-859000
CY2010	us-gaap	Availableforsale Securities Gross Realized Losses Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedLossesExcludingOtherThanTemporaryImpairments	0
CY2010	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1000
CY2010	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-816000
CY2010	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21577000
CY2010	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-56000
CY2010	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	94000
CY2010	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	50000
CY2010	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	67000
CY2010	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	3423000
CY2010	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	569000
CY2010	us-gaap	Interest Expense InterestExpense	689000
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16911000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.94
CY2010	us-gaap	Income Tax Reconciliation Nondeductible Expense Amortization IncomeTaxReconciliationNondeductibleExpenseAmortization	0
CY2010	cers	Purchase Commitment Payments PurchaseCommitmentPayments	900000
CY2010	cers	Income Tax Reconciliation Change In Fair Value Of Warrants IncomeTaxReconciliationChangeInFairValueOfWarrants	-13000
CY2010	cers	Payment For Royalty PaymentForRoyalty	2000000
CY2010	cers	Payment For Manufacturing Of Entity Products PaymentForManufacturingOfEntityProducts	8600000
CY2011	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7178000
CY2011	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	2000000
CY2011	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	112000	shares
CY2011	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2011	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	0
CY2010	cers	Proceeds From Landlord Financing Leasehold Improvement ProceedsFromLandlordFinancingLeaseholdImprovement	1100000
CY2010	cers	Revaluation Of Warrant Liability RevaluationOfWarrantLiability	39000
CY2010	cers	Income Tax Reconciliation Nondeductible Expense Lobbying Expenses IncomeTaxReconciliationNondeductibleExpenseLobbyingExpenses	112000
CY2010	cers	Income Tax Reconciliation Change In Carrying Value Of Investment IncomeTaxReconciliationChangeInCarryingValueOfInvestment	-107000
CY2010	cers	Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Purchases From Employee Stock Purchase Plans Value IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndPurchasesFromEmployeeStockPurchasePlansValue	369000
CY2010	cers	Income Tax Reconciliation Research Grant IncomeTaxReconciliationResearchGrant	166000
CY2010	cers	Income Tax Reconciliation Expiration Of Federal Net Operating Losses IncomeTaxReconciliationExpirationOfFederalNetOperatingLosses	596000
CY2010	cers	Acquisition Related Costs Net Of Gain On Non Controlling Equity Interest AcquisitionRelatedCostsNetOfGainOnNonControllingEquityInterest	182000
CY2011	us-gaap	Costmethod Investments Realized Gain Loss Excluding Other Than Temporary Impairments CostmethodInvestmentsRealizedGainLossExcludingOtherThanTemporaryImpairments	0
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-15924000
CY2011	us-gaap	Revenue From Grants RevenueFromGrants	2442000
CY2011	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	30602000
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1450000
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9273000
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	92000
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1850000
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17090000
CY2011	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	666000
CY2011	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	143000
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	11.52
CY2011	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5725000
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y5M19D
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	922000
CY2011	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2300000
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	1850000
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.36
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.45
CY2011	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2011	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	0
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1237000	shares
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	622000
CY2011	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	0
CY2011	us-gaap	Other Noncash Expense OtherNoncashExpense	5000
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	600000
CY2011	us-gaap	Entity Wide Disclosure On Geographic Areas Revenue From External Customers Attributed To Foreign Countries EntityWideDisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToForeignCountries	30602000
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15632000
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	563000
CY2011	us-gaap	Income Taxes Paid IncomeTaxesPaid	125000
CY2011	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-137000
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.81
CY2011	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9678000
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	158000
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3451000
CY2011	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	13000
CY2011	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	5008000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2169000	shares
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48050000	shares
CY2011	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2011	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-486000
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1304000
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16839000
CY2011	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	83000
CY2011	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-108000
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11618000
CY2011	us-gaap	Dilutive Securities DilutiveSecurities	0
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	465000	shares
CY2011	us-gaap	Operating Leases Rent Expense Minimum Rentals OperatingLeasesRentExpenseMinimumRentals	700000
CY2011	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2011	us-gaap	Operating Expenses OperatingExpenses	30433000
CY2011	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4158000
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-17461000
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48050000	shares
CY2011	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	601000
CY2011	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2011	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2011	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	4910000
CY2011	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	420000
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M28D
CY2011	us-gaap	Cost Of Goods Sold CostOfGoodsSold	18535000
CY2011	us-gaap	Revenues Revenues	33044000
CY2011	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	143000
CY2011	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-55000
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1850000
CY2011	cers	Income Tax Reconciliation Research Grant IncomeTaxReconciliationResearchGrant	0
CY2011	cers	Income Tax Reconciliation Expiration Of Federal Net Operating Losses IncomeTaxReconciliationExpirationOfFederalNetOperatingLosses	-1744000
CY2011	cers	Income Tax Reconciliation Nondeductible Expense Lobbying Expenses IncomeTaxReconciliationNondeductibleExpenseLobbyingExpenses	112000
CY2011	cers	Income Tax Reconciliation Change In Carrying Value Of Investment IncomeTaxReconciliationChangeInCarryingValueOfInvestment	0
CY2011	cers	Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Purchases From Employee Stock Purchase Plans Value IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndPurchasesFromEmployeeStockPurchasePlansValue	143000
CY2011	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0
CY2011	us-gaap	Gross Profit GrossProfit	12067000
CY2011	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0
CY2011	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0
CY2011	us-gaap	Interest Paid InterestPaid	1024000
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13595000	shares
CY2011	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2011	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	143000
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-16982000
CY2011	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-915000
CY2011	us-gaap	Availableforsale Securities Gross Realized Losses Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedLossesExcludingOtherThanTemporaryImpairments	0
CY2011	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	4000
CY2011	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-529000
CY2011	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23053000
CY2011	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-68000
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	143000
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-108000
CY2011	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	202000
CY2011	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	0
CY2011	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-336000
CY2011	us-gaap	Interest Expense InterestExpense	964000
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16982000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.37
CY2011	us-gaap	Income Tax Reconciliation Nondeductible Expense Amortization IncomeTaxReconciliationNondeductibleExpenseAmortization	0
CY2011	cers	Purchase Commitment Payments PurchaseCommitmentPayments	3600000
CY2011	cers	Income Tax Reconciliation Change In Fair Value Of Warrants IncomeTaxReconciliationChangeInFairValueOfWarrants	-165000
CY2011	cers	Payment For Royalty PaymentForRoyalty	2200000
CY2011	cers	Payment For Manufacturing Of Entity Products PaymentForManufacturingOfEntityProducts	9600000
CY2011	cers	Revaluation Of Warrant Liability RevaluationOfWarrantLiability	486000
CY2011	cers	Acquisition Related Costs Net Of Gain On Non Controlling Equity Interest AcquisitionRelatedCostsNetOfGainOnNonControllingEquityInterest	0
CY2012	dei	Trading Symbol TradingSymbol	CERS
CY2012	dei	Entity Registrant Name EntityRegistrantName	CERUS CORP
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0001020214
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Reclassifications</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain reclassifications have been made to prior period reported amounts to conform to the current period presentations. Previously the Company had presented its provision for income taxes as a component of other income (expense) , net on the Consolidated Statements of Operations. The Company has reclassified the provision for income taxes to a separate line item in the Consolidated Statements of Operations, and as presented in Note 17 and 19 to the Consolidated Financial Statements. This reclassification had no impact on net loss, total assets or total stockholders’ equity.</font></p> </div>
CY2012	us-gaap	Costmethod Investments Realized Gain Loss Excluding Other Than Temporary Impairments CostmethodInvestmentsRealizedGainLossExcludingOtherThanTemporaryImpairments	0
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-17300000
CY2012	us-gaap	Revenue From Grants RevenueFromGrants	91000
CY2012	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	36695000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2012	us-gaap	Goodwill Other Changes GoodwillOtherChanges	0
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-34000
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2506000
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14226000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y5M5D
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31000
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2541000
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15917000
CY2012	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	287000
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	180000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	30.44
CY2012	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Revenue</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company recognizes revenue in accordance with ASC Topic 605-25, <i>“Revenue Recognition—Arrangements with Multiple Deliverables,”</i> as applicable. Revenue is recognized when (i) persuasive evidence of an agreement exists; (ii) services have been rendered or product has been delivered; (iii) pricing is fixed or determinable; and (iv) collection is reasonably assured. The Company’s main sources of revenues for the years ended December 31, 2012, 2011 and 2010 were product revenue from sales of the INTERCEPT Blood System for platelets and plasma (“platelet and plasma systems”) and United States government grants and awards.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Revenue related to product sales is generally recognized when the Company fulfills its obligations for each element of an agreement. For all sales of the Company’s INTERCEPT Blood System products, the Company uses a binding purchase order and signed sales contract as evidence of a written agreement. The Company sells its platelet and plasma systems directly to blood banks, hospitals, universities, government agencies, as well as to distributors in certain regions. Generally, the Company’s contracts with its customers do not provide for open return rights, except within a reasonable time after receipt of goods in the case of defective or non-conforming product. Deliverables and the units of accounting vary according to the provisions of each purchase order or sales contract. For revenue arrangements with multiple elements, the Company determines whether the delivered elements meet the criteria as separate units of accounting. Such criteria require that the deliverable have stand-alone value to the customer and that if a general right of return exists relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Once the Company determines if the deliverable meets the criteria for a separate unit of accounting, the Company must determine how the consideration should be allocated between the deliverables and how the separate units of accounting should be recognized as revenue. Consideration received is allocated to elements that are identified as discrete units of accounting based on the best estimated selling price. The Company has determined that vendor specific objective evidence is not discernible due to the Company’s limited history of selling its products and variability in its pricing across the regions into which it sells its products. Since the Company’s products are novel and unique and are not sold by others, third-party evidence of selling price is unavailable.</font></p> </div>
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5329000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y5M27D
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	744000
CY2012	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1810000
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	2541000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.68
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.78
CY2012	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P10Y
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	98000	shares
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	48000
CY2012	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7603000
CY2012	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	-800000
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	156000	shares
CY2012	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2012	us-gaap	Defined Contribution Plan Maximum Annual Contribution Per Employee Percent DefinedContributionPlanMaximumAnnualContributionPerEmployeePercent	0.60	pure
CY2012	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	0
CY2012	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	0
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	386000	shares
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	685000
CY2012	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentration of Credit Risk</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and accounts receivable.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Pursuant to the Company’s investment policy, substantially all of the Company’s cash and cash equivalents are maintained at a major financial institution in the United States of high credit standing, which at times, may exceed federally insured limits. The Company has not experienced any losses in its cash accounts and believes it not exposed to any significant risk.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Concentrations of credit risk with respect to trade receivables exist. However, in connection with the Company’s revolving line of credit, as discussed in Note 11 in the Notes to Consolidated Financial Statements, the Company purchased a credit insurance policy that mitigates some of its credit risk, as the policy will pay either the Company or its lender on eligible claims filed on its outstanding receivables. On a regular basis, including at the time of sale, the Company performs credit evaluations of its customers. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company reserves against the accounts receivable on its consolidated balance sheets and records a charge on its consolidated statements of operations.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company had three customers and two customers that accounted for more than 10% of the Company’s outstanding trade receivables at December 31, 2012 and 2011, respectively. These customers cumulatively represented approximately 59% and 58% of the Company’s outstanding trade receivables at December 31, 2012 and 2011, respectively. To date, the Company has not experienced collection difficulties from these customers.</font></p> </div>
CY2012	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	0
CY2012	us-gaap	Other Noncash Expense OtherNoncashExpense	20000
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000
CY2012	us-gaap	Entity Wide Disclosure On Geographic Areas Revenue From External Customers Attributed To Foreign Countries EntityWideDisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToForeignCountries	36695000
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13917000
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	205000
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	162000
CY2012	us-gaap	Operating Leases Rent Expense Minimum Rentals OperatingLeasesRentExpenseMinimumRentals	600000
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	14000
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2012	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	900000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14911000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.30
CY2012	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	920000
CY2012	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Guarantee and Indemnification Arrangements</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company after December 31, 2002. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company’s technology infringes the intellectual property rights of a third party or claims that the sale or use of the Company’s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company generally provides for a one-year warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. During the year ended December 31, 2012, the Company provided for and settled the claims for warranty obligations of $0.9 million related to replacement costs for certain of its products that the Company identified were defective or had the potential of being defective. Prior to this incident, there have been very few warranty costs incurred. As a result, the Company had not accrued for any potential future warranty costs at December 31, 2011. In addition, the Company believes that the defective products and those that had the potential of being defective identified during the year ended December 31, 2012 are isolated. Accordingly, the Company has not accrued for any other incremental potential future warranty costs for its products at December 31, 2012.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">In connection with the warranty obligations provided for in relation to certain of its products during the year ended December 31, 2012, the Company filed a warranty claim against Fresenius, which Fresenius accepted. As a result, the Company recorded a current asset of $1.8 million on its consolidated balance sheets as of December 31, 2012 representing the full amount of the warranty claim against Fresenius as Fresenius will supply the Company with replacement products or credit notes for those defective or potentially defective products. The Company also wrote-down the value of certain unsalable inventory of $1.7 million related to these products as an offsetting warranty claim against Fresenius.</font></p> </div>
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13821000
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	81000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1199000
CY2012	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1663000
CY2012	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0
CY2012	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	537000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1782000	shares
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55061000	shares
CY2012	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2012	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-2059000
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1652000
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-15675000
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	99000
CY2012	us-gaap	Dilutive Securities DilutiveSecurities	-2059000
CY2012	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2012	us-gaap	Operating Expenses OperatingExpenses	33470000
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1761000
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-16360000
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54515000	shares
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3740000
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2012	cers	Income Tax Reconciliation Expiration Of Federal Net Operating Losses IncomeTaxReconciliationExpirationOfFederalNetOperatingLosses	-4352000
CY2012	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	546000	shares
CY2012	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2012	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	550000
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	7840000
CY2012	us-gaap	Interest Paid InterestPaid	460000
CY2011Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2011Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1808000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M2D
CY2012	us-gaap	Cost Of Goods Sold CostOfGoodsSold	20616000
CY2012	us-gaap	Revenues Revenues	36786000
CY2012	cers	Acquisition Related Costs Net Of Gain On Non Controlling Equity Interest AcquisitionRelatedCostsNetOfGainOnNonControllingEquityInterest	0
CY2012	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	9496000
CY2012Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5514000
CY2012	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	180000
CY2012	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1000
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2541000
CY2012	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0
CY2012	us-gaap	Gross Profit GrossProfit	16079000
CY2012	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	62000
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8716000	shares
CY2012	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2012	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	332000
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-15917000
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1625000
CY2012	us-gaap	Availableforsale Securities Gross Realized Losses Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedLossesExcludingOtherThanTemporaryImpairments	0
CY2012	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	19000
CY2012	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	86000
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25665000
CY2012	cers	Eligible To Receive Royalty Fee EligibleToReceiveRoyaltyFee	0.01	pure
CY2012	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	17000
CY2012	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-53000
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Amortization IncomeTaxReconciliationNondeductibleExpenseAmortization	48000
CY2012	cers	Purchase Commitment Payments PurchaseCommitmentPayments	7200000
CY2012	cers	Income Tax Reconciliation Change In Fair Value Of Warrants IncomeTaxReconciliationChangeInFairValueOfWarrants	-706000
CY2011Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4296000
CY2011Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5075000
CY2011Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2011Q1	us-gaap	Operating Expenses OperatingExpenses	7386000
CY2011Q1	us-gaap	Revenue From Grants RevenueFromGrants	436000
CY2011Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	6183000
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	242000
CY2012	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, inventory valuation, certain accrued liabilities, valuation and impairment of purchased intangibles and goodwill, valuation of warrants, valuation of stock options under share-based payments, valuation allowance of its deferred tax assets and uncertain income tax positions. The Company basis its estimates on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances, the results of which form its basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions.</font></p> </div>
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	202000
CY2012	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	0
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1971000
CY2012	us-gaap	Interest Expense InterestExpense	551000
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-17976000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.13
CY2012	cers	Expiration Of Non Cancelable Operating Leases Maximum Year ExpirationOfNonCancelableOperatingLeasesMaximumYear	2019
CY2012	cers	Inventory Life Finished Goods Period InventoryLifeFinishedGoodsPeriod	P2Y
CY2012	cers	Payment For Royalty PaymentForRoyalty	2700000
CY2012	cers	Inventory Life Work In Process Period InventoryLifeWorkInProcessPeriod	P1Y
CY2012	cers	Payment For Manufacturing Of Entity Products PaymentForManufacturingOfEntityProducts	12200000
CY2012	cers	Minimum Term Of Non Cancelable Operating Leases MinimumTermOfNonCancelableOperatingLeases	P1Y
CY2012	cers	Revaluation Of Warrant Liability RevaluationOfWarrantLiability	2059000
CY2012	cers	Safety Product Warranty Period SafetyProductWarrantyPeriod	P1Y
CY2012	cers	Income Tax Reconciliation Nondeductible Expense Lobbying Expenses IncomeTaxReconciliationNondeductibleExpenseLobbyingExpenses	51000
CY2012	cers	Income Tax Reconciliation Change In Carrying Value Of Investment IncomeTaxReconciliationChangeInCarryingValueOfInvestment	0
CY2012	cers	Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Purchases From Employee Stock Purchase Plans Value IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndPurchasesFromEmployeeStockPurchasePlansValue	349000
CY2012	cers	Income Tax Reconciliation Research Grant IncomeTaxReconciliationResearchGrant	0
CY2011Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	27000
CY2011Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51000
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4572000
CY2012Q1	us-gaap	Revenue From Grants RevenueFromGrants	91000
CY2012Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	8691000
CY2012Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2012Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1824000
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-8799000
CY2012Q1	us-gaap	Gross Profit GrossProfit	3177000
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-8834000
CY2012Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4227000
CY2012Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5966000
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35000
CY2012Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	50000
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4799000
CY2012Q2	us-gaap	Revenue From Grants RevenueFromGrants	0
CY2012Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9224000
CY2011Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1562000
CY2011Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7686000
CY2011Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2011Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3529000
CY2011Q1	us-gaap	Gross Profit GrossProfit	2654000
CY2011Q1	us-gaap	Net Income Loss NetIncomeLoss	-5098000
CY2011Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-779000
CY2011Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5528000
CY2011Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23000
CY2011Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	50000
CY2011Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5573000
CY2011Q2	us-gaap	Revenue From Grants RevenueFromGrants	0
CY2011Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	6753000
CY2011Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2011Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1994000
CY2011Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-6382000
CY2011Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2011Q2	us-gaap	Operating Expenses OperatingExpenses	8252000
CY2011Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4074000
CY2011Q2	us-gaap	Gross Profit GrossProfit	2679000
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	-6409000
CY2011Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-809000
CY2011Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6207000
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2012Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1712000
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1866000
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	8449000
CY2012Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5574000
CY2012Q2	us-gaap	Gross Profit GrossProfit	3650000
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-1907000
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2933000
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6686000
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	41000
CY2012Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51000
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2722000
CY2011Q3	us-gaap	Revenue From Grants RevenueFromGrants	1479000
CY2011Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	7770000
CY2011Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2011Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1814000
CY2011Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2304000
CY2011Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2011Q3	us-gaap	Operating Expenses OperatingExpenses	7245000
CY2011Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4726000
CY2011Q3	us-gaap	Gross Profit GrossProfit	3044000
CY2011Q3	us-gaap	Net Income Loss NetIncomeLoss	2260000
CY2011Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5026000
CY2011Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5380000
CY2011Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44000
CY2011Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51000
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4331000
CY2012Q3	us-gaap	Revenue From Grants RevenueFromGrants	0
CY2012Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	8252000
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2012Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1903000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3405000
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	8172000
CY2012Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4411000
CY2012Q3	us-gaap	Gross Profit GrossProfit	3841000
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-3460000
CY2012Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	926000
CY2012Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6219000
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	55000
CY2012Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	50000
CY2011Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-3333000
CY2011Q4	us-gaap	Revenue From Grants RevenueFromGrants	527000
CY2011Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9896000
CY2011Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2011Q4	us-gaap	Operating Expenses OperatingExpenses	7550000
CY2011Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6206000
CY2011Q4	us-gaap	Gross Profit GrossProfit	3690000
CY2011Q4	us-gaap	Net Income Loss NetIncomeLoss	-7735000
CY2011Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4353000
CY2011Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5938000
CY2011Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	49000
CY2011Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	50000
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-3598000
CY2012Q4	us-gaap	Revenue From Grants RevenueFromGrants	0
CY2012Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	10528000
CY2012Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2012Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2164000
CY2012Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1605000
CY2012Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2012Q4	us-gaap	Operating Expenses OperatingExpenses	9009000
CY2012Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5117000
CY2012Q4	us-gaap	Gross Profit GrossProfit	5411000
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-1716000
CY2012Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1993000
CY2012Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6794000
CY2012Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	111000
CY2012Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51000

Files In Submission

Name	View Source	Status
0001193125-13-103031-index-headers.html	Edgar Link	pending
0001193125-13-103031-index.html	Edgar Link	pending
0001193125-13-103031.txt	Edgar Link	pending
0001193125-13-103031-xbrl.zip	Edgar Link	pending
cers-20121231.xml	Edgar Link	completed
cers-20121231.xsd	Edgar Link	pending
cers-20121231_cal.xml	Edgar Link	unprocessable
cers-20121231_def.xml	Edgar Link	unprocessable
cers-20121231_lab.xml	Edgar Link	unprocessable
cers-20121231_pre.xml	Edgar Link	unprocessable
d451888d10k.htm	Edgar Link	pending
d451888dex1015.htm	Edgar Link	pending
d451888dex1024.htm	Edgar Link	pending
d451888dex103.htm	Edgar Link	pending
d451888dex1039.htm	Edgar Link	pending
d451888dex1042.htm	Edgar Link	pending
d451888dex121.htm	Edgar Link	pending
d451888dex211.htm	Edgar Link	pending
d451888dex231.htm	Edgar Link	pending
d451888dex311.htm	Edgar Link	pending
d451888dex312.htm	Edgar Link	pending
d451888dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g451888g86h41.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CERS
Cerus Corp Stock $cers

2011 Q4 Form 10-K Financial Statement

#000119312513103031 Filed on March 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CERS Cerus Corp Stock $cers

2011 Q4 Form 10-K Financial Statement

#000119312513103031 Filed on March 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CERS
Cerus Corp Stock $cers